BRIEF-Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program

Reuters
03 Mar
BRIEF-Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program

March 3 (Reuters) - Nkgen Biotech Inc NKGN.O:

  • NKGEN BIOTECH ANNOUNCES ADMINISTRATION OF FIRST DOSE OF TROCULEUCEL TO STROKE PATIENT UNDER FDA-CLEARED COMPASSIONATE USE PROGRAM

Source text: ID:nGNX4k4GY1

Further company coverage: NKGN.O

(Reuters.Briefs@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10